ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO343

Plasma Leucine-Rich Alpha-2-Glycoprotein 1 Predicts Cardiovascular Disease Risk in ESRD

Session Information

Category: Hypertension and CVD

  • 1403 Hypertension and CVD: Mechanisms

Authors

  • Liu, Chia-Yu, Far Eastern Memorial Hospital, New Taipei City, Taiwan
  • Shu, Kai-Hsiang, National Taiwan University, Taipei, TAIWAN, Taiwan
  • Chiu, Yen-Ling, Far Eastern Memorial Hospital, New Taipei City, Taiwan
Background

Plasma Leucine-Rich alpha-2-Glycoprotein 1(LRG1) is an innovative biomarker for inflammation and angiogenetic diseases. End-stage renal disease (ESRD) is associated with adverse outcomes including inflammation, atherosclerosis, and premature mortality. However, whether levels of plasma LRG1 correlate with the co-morbidities of ESRD patients is unknown.

Methods

Plasma LRG-1 and high-sensitivity C-reactive protein were analyzed by ELISA in samples from 169 hemodialysis patients from the Immunity in ESRD study (iESRD study). Through history taking and detailed chart reviews, baseline co-morbidities were recorded. Peripheral blood monocyte and T cell subsets were assessed by multicolor flow cytometry.

Results

In the univariate analysis, LRG1 was found to be associated with the existence of cardiovascular disease (CVD) and peripheral arterial occlusive disease (PAOD). In multivariate-adjusted logistic regression models, higher LRG1 tertile was significantly associated with PAOD (odds ratio = 3.49), CVD (odds ratio = 1.65), but not with coronary artery disease, history of myocardial infarction, or stroke after adjusting for gender, hemoglobin, diabetes, hypertension, and level of C-reactive protein. In addition, the level of LRG-1 positively correlated with IL-6 and CRP and more advanced T cell differentiation, indicating the participation of LRG1 in the progression of atherosclerosis.

Conclusion

In the univariate analysis, LRG1 was found to be associated with the existence of cardiovascular disease (CVD) and peripheral arterial occlusive disease (PAOD). In multivariate-adjusted logistic regression models, higher LRG1 tertile was significantly associated with PAOD (odds ratio = 3.49), CVD (odds ratio = 1.65), but not with coronary artery disease, history of myocardial infarction, or stroke after adjusting for gender, hemoglobin, diabetes, hypertension, and level of C-reactive protein. In addition, the level of LRG-1 positively correlated with IL-6 and CRP and more advanced T cell differentiation, indicating the participation of LRG1 in the progression of atherosclerosis.